Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (501-510 of 692) with videos related to

Pageof 70
Sort By:
Journal of Vascular and Interventional Radiology : JVIR|August 8, 2022
Evaluation of an Integrated Spectroscopy and Classification Platform for Point-of-Care Core Needle Biopsy Assessment: Performance Characteristics from Ex Vivo Renal Mass BiopsiesKrishna Nand Keshavamurthy, Dmitry V Dylov, Siavash Yazdanfar, et al.
European Urology|April 23, 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical CharacteristicsBastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2000
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigensZ G Wang, L J Williams, X F Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancerMichael J Morris, William P Tong, Carlos Cordon-Cardo, et al.
Nuclear Medicine Communications|February 28, 2012
Computer-aided quantitative bone scan assessment of prostate cancer treatment responseMatthew S Brown, Gregory H Chu, Hyun J Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate CancerHimisha Beltran, Adam Jendrisak, Mark Landers, et al.
Molecular & Cellular Proteomics : MCP|July 25, 2014
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancerArpi Nazarian, Kevin Lawlor, San San Yi, et al.
Nature Medicine|January 14, 1998
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progressionC N Papandreou, B Usmani, Y Geng, et al.
Pageof 70

Showing results (501-510 of 692) with videos related to

Sort By:
Pageof 70
Journal of Vascular and Interventional Radiology : JVIR|August 8, 2022
Evaluation of an Integrated Spectroscopy and Classification Platform for Point-of-Care Core Needle Biopsy Assessment: Performance Characteristics from Ex Vivo Renal Mass BiopsiesKrishna Nand Keshavamurthy, Dmitry V Dylov, Siavash Yazdanfar, et al.
European Urology|April 23, 2020
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical CharacteristicsBastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2000
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigensZ G Wang, L J Williams, X F Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancerMichael J Morris, William P Tong, Carlos Cordon-Cardo, et al.
Nuclear Medicine Communications|February 28, 2012
Computer-aided quantitative bone scan assessment of prostate cancer treatment responseMatthew S Brown, Gregory H Chu, Hyun J Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate CancerHimisha Beltran, Adam Jendrisak, Mark Landers, et al.
Molecular & Cellular Proteomics : MCP|July 25, 2014
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancerArpi Nazarian, Kevin Lawlor, San San Yi, et al.
Nature Medicine|January 14, 1998
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progressionC N Papandreou, B Usmani, Y Geng, et al.
Pageof 70